Vivesto and CEO Francois Martelet have agreed on ending the employment relationship

Vivesto AB (“Vivesto” or the “Company”), an oncology-focused specialty pharmaceutical company, hereby announces that the Board of Directors of the Company has today agreed with the Company’s CEO, Francois Martelet, to mutually terminate his employment. Pursuant to the agreement, Francois’ employment will end on 21 July 2022.

Vivesto has commenced the search for a new CEO.

Francois Martelet has been CEO since 15 March 2020.

Peter Zonabend, Chairman of the Board of Vivesto, said: “On behalf of the Board, I would like to express my gratitude to Francois for his service and determination during his tenure at Vivesto. We wish him the best for his next endeavours.”

Francois Martelet said: “It has been an incredible honour to lead Vivesto during this period of transformation and I am pleased about what we have achieved together. My team and I are proud to have strengthened Vivesto’s finances in a challenging market environment and to have started the ‘string of pearls’ strategy to build Vivesto’s pipeline through in-licensing and M&A. I want to offer my thanks to the Board, and I wish Vivesto every success for the future.”

About Vivesto AB
Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Vivesto has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Vivesto’s shares are traded on Nasdaq Stockholm (VIVE).